Active Biotech

April 26, 2012 02:43 ET

Active Biotech AB Interim report January - March 2012

LUND, SWEDEN--(Marketwire - Apr 26, 2012) -

  * Laquinimod - submission of application for regulatory approval in the
                 EU planned for second half of 2012
               - Phase III data presented at the Annual Meeting of the
                 American Academy of Neurology (AAN)

  * TASQ       - a Phase I investigator-sponsored clinical trial is
                 under way
               - enrolment of patients to Phase III study proceeding
                 according to schedule

  * ANYARA     - Phase III trial continuing according to plan

  * 57-57      - a clinical trial in systemic sclerosis/scleroderma
                 in progress

  * ISI        - project is proceeding as planned

  * Net sales SEK 2.6 M (2.7)

  * Operating loss SEK 100.7 M (loss: 70.9)

  * Net loss SEK 99.0 M (loss: 69.3 )

  * Loss per share for the period was SEK 1.44 (loss: 1.02)

This report is also available at www.activebiotech.com

Active Biotech AB Interim report January - March 2012: http://hugin.info/1002/R/1605995/508858.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE [HUG#1605995]

Contact Information

  • For further information, please contact:

    Tomas Leanderson
    President and CEO
    Tel: +46 (0)46 19 20 95

    Hans Kolam
    CFO
    Tel: +46 (0)46 19 20 44


    Active Biotech AB
    (Corp Reg. No. 556223-9227)
    PO Box 724, SE-220 07 Lund
    Tel: +46 (0)46 19 20 00
    Fax: +46 (0)46 19 11 00